{
    "2021-08-18": [
        [
            {
                "time": "2023-10-17",
                "original_text": "FDA Approves Eli Lilly's Jardiance For Heart Failure",
                "features": {
                    "keywords": [
                        "FDA",
                        "Approves",
                        "Eli Lilly",
                        "Jardiance",
                        "Heart Failure"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-17",
                "original_text": "Is Eli Lilly (LLY) A Smart Long-Term Buy?",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Long-Term Buy"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-17",
                "original_text": "US FDA approves JardianceÂ® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction",
                "features": {
                    "keywords": [
                        "US FDA",
                        "approves",
                        "Jardiance",
                        "heart failure",
                        "reduced ejection fraction"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-17",
                "original_text": "3 Big Drug/Biotech Outperformers Worth Keeping an Eye On",
                "features": {
                    "keywords": [
                        "Drug",
                        "Biotech",
                        "Outperformers"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-17",
                "original_text": "The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline",
                "features": {
                    "keywords": [
                        "Daily Biotech Pulse",
                        "AzurRx",
                        "Agios",
                        "Mitapivat",
                        "Priority Review",
                        "FDA Nod",
                        "GlaxoSmithKline"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}